Report Detail

Request for Sample of this report

Pharma & Healthcare Global Renin-Angiotensin-System (RAS)-Acting Agent Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

  • RnM4744846
    • |
  • 28 September, 2026
    • |
  • Global
    • |
  • 92 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Renin-Angiotensin-System (RAS)-Acting Agent market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report is a detailed and comprehensive analysis for global Renin-Angiotensin-System (RAS)-Acting Agent market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Renin-Angiotensin-System (RAS)-Acting Agent market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Renin-Angiotensin-System (RAS)-Acting Agent market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Renin-Angiotensin-System (RAS)-Acting Agent market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Renin-Angiotensin-System (RAS)-Acting Agent market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Renin-Angiotensin-System (RAS)-Acting Agent
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Renin-Angiotensin-System (RAS)-Acting Agent market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis AG, Pfizer, Inc., AstraZeneca plc, Merck & Co., Inc., Sanofi S.A., Bristol-Myers Squibb Company, Daiichi Sankyo Company,Limited, Takeda Pharmaceutical Company Limited, Boehringer lngelheim GmbH, Johnson & Johnson, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Renin-Angiotensin-System (RAS)-Acting Agent market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Angiotensin Converting Enzyme Inhibitors (ACEi)
Angiotensin Receptor Blockers (ARBs)
Market segment by Application
Hypertension
Heart Failure
Chronic Kidney Disease
Other
Major players covered
Novartis AG
Pfizer, Inc.
AstraZeneca plc
Merck & Co., Inc.
Sanofi S.A.
Bristol-Myers Squibb Company
Daiichi Sankyo Company,Limited
Takeda Pharmaceutical Company Limited
Boehringer lngelheim GmbH
Johnson & Johnson
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Renin-Angiotensin-System (RAS)-Acting Agent product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Renin-Angiotensin-System (RAS)-Acting Agent, with price, sales quantity, revenue, and global market share of Renin-Angiotensin-System (RAS)-Acting Agent from 2021 to 2026.
Chapter 3, the Renin-Angiotensin-System (RAS)-Acting Agent competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Renin-Angiotensin-System (RAS)-Acting Agent breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Renin-Angiotensin-System (RAS)-Acting Agent market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Renin-Angiotensin-System (RAS)-Acting Agent.
Chapter 14 and 15, to describe Renin-Angiotensin-System (RAS)-Acting Agent sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Angiotensin Converting Enzyme Inhibitors (ACEi)
    • 1.3.3 Angiotensin Receptor Blockers (ARBs)
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hypertension
    • 1.4.3 Heart Failure
    • 1.4.4 Chronic Kidney Disease
    • 1.4.5 Other
  • 1.5 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size & Forecast
    • 1.5.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity (2021-2032)
    • 1.5.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Novartis AG
    • 2.1.1 Novartis AG Details
    • 2.1.2 Novartis AG Major Business
    • 2.1.3 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
    • 2.1.4 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Novartis AG Recent Developments/Updates
  • 2.2 Pfizer, Inc.
    • 2.2.1 Pfizer, Inc. Details
    • 2.2.2 Pfizer, Inc. Major Business
    • 2.2.3 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
    • 2.2.4 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Pfizer, Inc. Recent Developments/Updates
  • 2.3 AstraZeneca plc
    • 2.3.1 AstraZeneca plc Details
    • 2.3.2 AstraZeneca plc Major Business
    • 2.3.3 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
    • 2.3.4 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 AstraZeneca plc Recent Developments/Updates
  • 2.4 Merck & Co., Inc.
    • 2.4.1 Merck & Co., Inc. Details
    • 2.4.2 Merck & Co., Inc. Major Business
    • 2.4.3 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
    • 2.4.4 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Merck & Co., Inc. Recent Developments/Updates
  • 2.5 Sanofi S.A.
    • 2.5.1 Sanofi S.A. Details
    • 2.5.2 Sanofi S.A. Major Business
    • 2.5.3 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
    • 2.5.4 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Sanofi S.A. Recent Developments/Updates
  • 2.6 Bristol-Myers Squibb Company
    • 2.6.1 Bristol-Myers Squibb Company Details
    • 2.6.2 Bristol-Myers Squibb Company Major Business
    • 2.6.3 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
    • 2.6.4 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Bristol-Myers Squibb Company Recent Developments/Updates
  • 2.7 Daiichi Sankyo Company,Limited
    • 2.7.1 Daiichi Sankyo Company,Limited Details
    • 2.7.2 Daiichi Sankyo Company,Limited Major Business
    • 2.7.3 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
    • 2.7.4 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Daiichi Sankyo Company,Limited Recent Developments/Updates
  • 2.8 Takeda Pharmaceutical Company Limited
    • 2.8.1 Takeda Pharmaceutical Company Limited Details
    • 2.8.2 Takeda Pharmaceutical Company Limited Major Business
    • 2.8.3 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
    • 2.8.4 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
  • 2.9 Boehringer lngelheim GmbH
    • 2.9.1 Boehringer lngelheim GmbH Details
    • 2.9.2 Boehringer lngelheim GmbH Major Business
    • 2.9.3 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
    • 2.9.4 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Boehringer lngelheim GmbH Recent Developments/Updates
  • 2.10 Johnson & Johnson
    • 2.10.1 Johnson & Johnson Details
    • 2.10.2 Johnson & Johnson Major Business
    • 2.10.3 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product and Services
    • 2.10.4 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Johnson & Johnson Recent Developments/Updates

3 Competitive Environment: Renin-Angiotensin-System (RAS)-Acting Agent by Manufacturer

  • 3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Manufacturer (2021-2026)
  • 3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Renin-Angiotensin-System (RAS)-Acting Agent by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Renin-Angiotensin-System (RAS)-Acting Agent Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Renin-Angiotensin-System (RAS)-Acting Agent Manufacturer Market Share in 2025
  • 3.5 Renin-Angiotensin-System (RAS)-Acting Agent Market: Overall Company Footprint Analysis
    • 3.5.1 Renin-Angiotensin-System (RAS)-Acting Agent Market: Region Footprint
    • 3.5.2 Renin-Angiotensin-System (RAS)-Acting Agent Market: Company Product Type Footprint
    • 3.5.3 Renin-Angiotensin-System (RAS)-Acting Agent Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Region
    • 4.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Region (2021-2032)
    • 4.1.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Region (2021-2032)
  • 4.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2021-2032)
  • 4.3 Europe Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2021-2032)
  • 4.5 South America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2021-2032)
  • 5.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Type (2021-2032)
  • 5.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2021-2032)
  • 6.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Application (2021-2032)
  • 6.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2021-2032)
  • 7.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2021-2032)
  • 7.3 North America Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
    • 7.3.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2021-2032)
  • 8.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2021-2032)
  • 8.3 Europe Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
    • 8.3.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Region
    • 9.3.1 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2021-2032)
  • 10.2 South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2021-2032)
  • 10.3 South America Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
    • 10.3.1 South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
    • 11.3.1 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Renin-Angiotensin-System (RAS)-Acting Agent Market Drivers
  • 12.2 Renin-Angiotensin-System (RAS)-Acting Agent Market Restraints
  • 12.3 Renin-Angiotensin-System (RAS)-Acting Agent Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Renin-Angiotensin-System (RAS)-Acting Agent and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Renin-Angiotensin-System (RAS)-Acting Agent
  • 13.3 Renin-Angiotensin-System (RAS)-Acting Agent Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Renin-Angiotensin-System (RAS)-Acting Agent Typical Distributors
  • 14.3 Renin-Angiotensin-System (RAS)-Acting Agent Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Renin-Angiotensin-System (RAS)-Acting Agent. Industry analysis & Market Report on Renin-Angiotensin-System (RAS)-Acting Agent is a syndicated market report, published as Global Renin-Angiotensin-System (RAS)-Acting Agent Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Renin-Angiotensin-System (RAS)-Acting Agent market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo